Advertisement

Topics

European Commission approves Novartis's Zykadia for ALK-positive NSCLC patients

19:00 EDT 2 Jul 2017 | Pharmaceutical Technology

The European Commission (EC) has given approval for the expansion of use for Swiss healthcare company Novartis's Zykadia (ceritinib) drug for treatment of advanced non-small cell lung cancer (NSCLC) in the EU. 

Original Article: European Commission approves Novartis's Zykadia for ALK-positive NSCLC patients

NEXT ARTICLE

More From BioPortfolio on "European Commission approves Novartis's Zykadia for ALK-positive NSCLC patients"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

Healthcare
Health care (or healthcare) is the diagnosis, treatment, and prevention of disease, illness, injury, and other physical and mental impairments in humans. Health care is delivered by practitioners in medicine, chiropractic, dentistry, nursing, pharmacy, a...

The Top 100 Pharmaceutical Companies
Top 10 biotech and pharmaceutical companies worldwide based on market value in 2015 2015 ranking of the global top 10 biotech and pharmaceutical companies based on revenue (in billion U.S. dollars) Johnson & Johnson, U.S. 74...

Pharmacy
Pharmacy is the science and technique of preparing as well as dispensing drugs and medicines. It is a health profession that links health sciences with chemical sciences and aims to ensure the safe and effective use of pharmaceutical drugs. The scope of...